Marc Goodman

UBS analyst Marc Goodman upgraded AbbVie (NYSE: ABBV) from Neutral to Buy and raised the price target to $67 based on several key factors. Goodman noted that one attractive item is the potential Shire deal, which would diversify AbbVie’s portfolio into the rare disease sector. Even if the...

In a report published Tuesday, UBS Securities analyst Marc Goodman upgraded the rating on Allergan (NYSE: AGN) from Neutral to Buy, and raised the price target from $180.00 to $200.00. In the report, UBS Securities noted, “Investors have been waiting for 2 Allergan events: a restructuring and an...

In a report published Friday, UBS Investment Research analyst Marc Goodman reiterated a Buy rating on Mylan (NASDAQ: MYL), and raised the price target from $36.00 to $39.00. In the report, UBS Investment Research noted, “Mgt did a good job detailing key drivers (injectables, respiratory, ARV,...

Analysts Marc Goodman and Ami Fadia at UBS have released an update on Pfizer Inc. (NYSE: PFE). UBS recently attended an investor dinner with Pfizer’s CFO and IR. The key takeaways from the meeting, according to analysts, are the company’s commitment to 2012 guidance and its willingness to cut...